LSTM Home > LSTM Research > LSTM Online Archive

NIMble innovation—a networked model for public antibiotic trials

Glover, Rebecca, Singer, Andrew, Roberts, Adam ORCID: and Kirchhelle, Claas (2021) 'NIMble innovation—a networked model for public antibiotic trials'. Lancet Microbe, Vol 2, Issue 11, E637-E644.

[img] Text
THELANCETMICROBE-D-21-00189_R1-2(2).pdf - Accepted Version
Restricted to Repository staff only

Download (2MB)
1-s2.0-S2666524721001828-main.pdf - Published Version
Available under License Creative Commons Attribution.

Download (429kB) | Preview


Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with (1) conducting all trial stages up to market authorisation, including small-scale compound production; (2) negotiating licensing agreements for global production and distribution by industry partners; and (3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model's benefits for unblocking the public and private antibiotic pipeline.

Item Type: Article
Subjects: QV Pharmacology > Drug Standardization. Pharmacognosy. Medicinal Plants > QV 771 Standardization and evaluation of drugs
QW Microbiology and Immunology > QW 45 Microbial drug resistance. General or not elsewhere classified.
WB Practice of Medicine > Therapeutics > WB 330 Drug therapy
Faculty: Department: Biological Sciences > Department of Tropical Disease Biology
Digital Object Identifer (DOI):
Depositing User: Marie Hatton
Date Deposited: 18 Oct 2021 16:45
Last Modified: 16 Jun 2023 06:42


View details

Actions (login required)

Edit Item Edit Item